Navigation Links
Suven Life Sciences Presenting Pre-clinical data of their,NCE’s SUVN-502 and SUVN-507at International Brain Research,Organization (IBRO) 2007 World Congress of Neuroscience

HYDERABAD, India, July 5th, 2007 – Several data presentations from Suven’s portfolio of investigational neuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 World Congress of Neuroscience to be held at Melbourne, Australia during July 12-17, 2007.

Scientists from Suven Discovery Research will be presenting new data for 4 promising areas of neuroscience viz. Alzheimer’s, Schizophrenia, Parkinson and Obesity diseases. These areas present significant unmet medical need for which current treatment options are insufficient. Suven has a number of programs in each of these areas, focusing on novel approaches that may lead to the development of new therapies for patients.
Suven is presenting the data on their leading preclinical candidates SUVN-502 and SUVN-507 at IBRO 2007 world congress of Neuroscience .

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven’s CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders and Neurodegeneration.

Suven Life Sciences, a Hyderabad based Life Sciences Company, pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995 in its endeavor to become collaborative research partner (CRP) for global life science companies has embarked on new business model “Drug Discovery and Development Support Services” (DDDSS) with the onset of Intellectual Property Regime in India since January 2005.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven ’s commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 190 professionals with the state of the art infrastructure for Drug Discovery and development activities with 30 clinical research professionals and the front-end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive.

Serene Chambers, Road No.5, Avenue 7, Banjara Hills Hyderabad 500034, India

Tel: 91-40-2354 1142 Fax: 91-40-2354 1152 Email:


Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
7. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
10. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
11. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
Post Your Comments:
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
Breaking Medicine News(10 mins):